Breaking News, Collaborations & Alliances

Isis, AstraZeneca Expand Development Partnership

To discover and develop new delivery methods for antisense oligonucleotides

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Isis Pharmaceuticals and AstraZeneca entered a strategic alliance to discover and develop new delivery methods for antisense oligonucleotides that target the desired tissue more effectively. The alliance will initially focus on oncology, cardiovascular and metabolic diseases (CVMD). The agreement builds on an existing collaboration supporting AZ’s R&D capabilities for antisense oligonucleotide-based therapeutics and RNA biology.     The new delivery methods will aim to enhance the acce...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters